News Center
-
Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League, Leads Delegation to Inspect Chia Tai Tianqing, Focusing on Innovative Development and Youth Talent Cultivation
On the morning of April 25, a delegation led by Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League and Chairman of the All-China Youth Federation, visited CTTQ, a core enterprise of Sino Biopharmaceutical (1177.HK), for inspection and guidance.View -
Sino Biopharmaceutical's "Defu Combination" Approved for Fourth Indication, with an Objective Response Rate of 72.41%!
On April 17, the official website of the National Medical Products Administration (NMPA) showed that the 4th indication for the Class 1 new drug "Defu Combination" from CTTQ, a core enterprise of Sino Biopharmaceutical (1177.HK)—Benmelstobart (Andewei®) combined with Anlotinib capsules (Fukewei®)—has been approved for marketing for the treatment of advanced or unresectable alveolar soft tissue sarcoma (ASPS).View -
Jointly Promoting New Development in China-UAE Economic and Trade Cooperation! China-UAE Business and Investment Promotion Conference Held in Beijing, Eric Tse Invited to Attend the Opening Ceremony
On April 13, the "China-UAE Business and Investment Promotion Conference", jointly hosted by the Ministry of Commerce of the People's Republic of China and the Ministry of Foreign Trade of the United Arab Emirates, was held in Beijing.View -
Sino Biopharmaceutical Enters the Era of Domesticated "10,000-Liter Scale" Biologic Production Lines
From "emerging and cultivating" to a "strategic pillar", as China's biopharmaceutical industry enters a new stage of high-quality development, mere capacity expansion is no longer the sole measure of a company's core competitiveness.View
Science for a healthier world
